CAR T-cell immunotherapy: The path from the by-road to the freeway?

Molecular Oncology

Volumn 9, Issue 10, 2015, Pages 1994-2018

  Whilding, Lynsey M ^a   Maher, John ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BARNET HOSPITAL   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cancer; Chimeric antigen receptor; Immunotherapy; Solid tumours; T cells

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; HYBRID PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CYTOKINE RELEASE SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOXIA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY;

HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84951801466     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.10.012     Document Type: Review

References (234)

1. Achkova D., Spicer J., Maher J. Development of immunotherapy for anaplastic large cell lymphoma (ALCL) using CSF1R retargeted human T lymphocytes 2015, Proceedings of the American Association for Cancer Research Meeting, Philadelphia, Pennsylvania, Abstract 3144.
2. Adusumilli P.S., Cherkassky L., Villena-Vargas J., Colovos C., Servais E., Plotkin J., Jones D.R., Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 2014, 6. 261ra151.
3. Ahmad A.S., Ormiston-Smith N., Sasieni P.D. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br. J. Cancer 2015, 112:943-947.
4. Ahmed N., Brawley V.S., Hegde M., Robertson C., Ghazi A., Gerken C., Liu E., Dakhova O., Ashoori A., Corder A., Gray T., Wu M.F., Liu H., Hicks J., Rainusso N., Dotti G., Mei Z., Grilley B., Gee A., Rooney C.M., Brenner M.K., Heslop H.E., Wels W.S., Wang L.L., Anderson P., Gottschalk S. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2015, 33:1688-1696.
5. Ahmed N., Salsman V.S., Kew Y., Shaffer D., Powell S., Zhang Y.J., Grossman R.G., Heslop H.E., Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:474-485.
6. Ahmed N., Salsman V.S., Yvon E., Louis C.U., Perlaky L., Wels W.S., Dishop M.K., Kleinerman E.E., Pule M., Rooney C.M., Heslop H.E., Gottschalk S. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther.: J. Am. Soc. Gene Ther. 2009, 17:1779-1787.
7. Akishima-Fukasawa Y., Nakanishi Y., Ino Y., Moriya Y., Kanai Y., Hirohashi S. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am. J. Clin. Pathol. 2009, 132:202-210. quiz 307.
8. Allard B., Pommey S., Smyth M.J., Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:5626-5635.
9. Almasbak H., Walseng E., Kristian A., Myhre M.R., Suso E.M., Munthe L.A., Andersen J.T., Wang M.Y., Kvalheim G., Gaudernack G., Kyte J.A. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 2015, 22:391-403.
10. Altenschmidt U., Kahl R., Moritz D., Schnierle B.S., Gerstmayer B., Wels W., Groner B. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 1996, 2:1001-1008.
11. Altvater B., Landmeier S., Pscherer S., Temme J., Juergens H., Pule M., Rossig C. 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. Cancer Immunol. Immunother. 2009, 58:1991-2001.
12. Anurathapan U., Chan R.C., Hindi H.F., Mucharla R., Bajgain P., Hayes B.C., Fisher W.E., Heslop H.E., Rooney C.M., Brenner M.K., Leen A.M., Vera J.F. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol. Ther.: J. Am. Soc. Gene Ther. 2014, 22:623-633.
13. Araki K., Turner A.P., Shaffer V.O., Gangappa S., Keller S.A., Bachmann M.F., Larsen C.P., Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
14. Asai H., Fujiwara H., An J., Ochi T., Miyazaki Y., Nagai K., Okamoto S., Mineno J., Kuzushima K., Shiku H., Inoue H., Yasukawa M. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One 2013, 8:e56820.
15. Ayala A., Chung C.S., Grutkoski P.S., Song G.Y. Mechanisms of immune resolution. Crit. Care Med. 2003, 31:S558-S571.
16. Beatty G.L., Haas A.R., Maus M.V., Torigian D.A., Soulen M.C., Plesa G., Chew A., Zhao Y., Levine B.L., Albelda S.M., Kalos M., June C.H. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2014, 2:112-120.
17. Beavis P.A., Milenkovski N., Henderson M.A., John L.B., Allard B., Loi S., Kershaw M.H., Stagg J., Darcy P.K. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res. 2015, 3:506-517.
18. Ben-Shoshan J., Maysel-Auslender S., Mor A., Keren G., George J. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur. J. Immunol. 2008, 38:2412-2418.
19. Berdien B., Mock U., Atanackovic D., Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014, 21:539-548.
20. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl. J. Med. 2012, 366:2455-2465.
21. Brenner M.K. CAR T cells for acute myeloid leukemia: the LeY of the land. Mol. Ther. 2013, 21:1983-1984.
22. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., Bartido S., Stefanski J., Taylor C., Olszewska M., Borquez-Ojeda O., Qu J., Wasielewska T., He Q., Bernal Y., Rijo I.V., Hedvat C., Kobos R., Curran K., Steinherz P., Jurcic J., Rosenblat T., Maslak P., Frattini M., Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013, 5. 177ra138.
23. Brentjens R.J., Latouche J.B., Santos E., Marti F., Gong M.C., Lyddane C., King P.D., Larson S., Weiss M., Riviere I., Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 2003, 9:279-286.
24. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., Taylor C., Yeh R., Bartido S., Borquez-Ojeda O., Olszewska M., Bernal Y., Pegram H., Przybylowski M., Hollyman D., Usachenko Y., Pirraglia D., Hosey J., Santos E., Halton E., Maslak P., Scheinberg D., Jurcic J., Heaney M., Heller G., Frattini M., Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
25. Brentjens R.J., Santos E., Nikhamin Y., Yeh R., Matsushita M., La Perle K., Quintas-Cardama A., Larson S.M., Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2007, 13:5426-5435.
26. Bridgeman J.S., Hawkins R.E., Bagley S., Blaylock M., Holland M., Gilham D.E. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 2010, 184:6938-6949.
27. Brown C.E., Badie B., Barish M.E., Weng L., Ostberg J.R., Chang W.C., Naranjo A., Starr R., Wagner J., Wright C., Zhai Y., Bading J.R., Ressler J.A., Portnow J., D'Apuzzo M., Forman S.J., Jensen M.C. Bioactivity and safety of IL13Ralpha2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2015, 21:4062-4072.
28. Budde L.E., Berger C., Lin Y., Wang J., Lin X., Frayo S.E., Brouns S.A., Spencer D.M., Till B.G., Jensen M.C., Riddell S.R., Press O.W. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One 2013, 8:e82742.
29. Calcinotto A., Filipazzi P., Grioni M., Iero M., De Milito A., Ricupito A., Cova A., Canese R., Jachetti E., Rossetti M., Huber V., Parmiani G., Generoso L., Santinami M., Borghi M., Fais S., Bellone M., Rivoltini L. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012, 72:2746-2756.
30. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., Varela-Rohena A., Haines K.M., Heitjan D.F., Albelda S.M., Carroll R.G., Riley J.L., Pastan I., June C.H. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3360-3365.
31. Caruana I., Savoldo B., Hoyos V., Weber G., Liu H., Kim E.S., Ittmann M.M., Marchetti D., Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 2015, 21:524-529.
32. Chang C.L., Hsu Y.T., Wu C.C., Lai Y.Z., Wang C., Yang Y.C., Wu T.C., Hung C.F. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res. 2013, 73:119-127.
33. Chicaybam L., Bonamino M.H. Construction and validation of an activating and inhibitory chimeric antigen receptor (CAR) system 2015, Proceedings of the American Association for Cancer Research Meeting, Philadelphia, Pennsylvania, Abstract number 3156.
34. Chmielewski M., Kopecky C., Hombach A.A., Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011, 71:5697-5706.
35. Chow K.K., Naik S., Kakarla S., Brawley V.S., Shaffer D.R., Yi Z., Rainusso N., Wu M.F., Liu H., Kew Y., Grossman R.G., Powell S., Lee D., Ahmed N., Gottschalk S. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther.: J. Am. Soc. Gene Ther. 2013, 21:629-637.
36. Cieri N., Camisa B., Cocchiarella F., Forcato M., Oliveira G., Provasi E., Bondanza A., Bordignon C., Peccatori J., Ciceri F., Lupo-Stanghellini M.T., Mavilio F., Mondino A., Bicciato S., Recchia A., Bonini C. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013, 121:573-584.
37. Craddock J.A., Lu A., Bear A., Pule M., Brenner M.K., Rooney C.M., Foster A.E. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 2010, 33:780-788.
38. Cruz C.R., Micklethwaite K.P., Savoldo B., Ramos C.A., Lam S., Ku S., Diouf O., Liu E., Barrett A.J., Ito S., Shpall E.J., Krance R.A., Kamble R.T., Carrum G., Hosing C.M., Gee A.P., Mei Z., Grilley B.J., Heslop H.E., Rooney C.M., Brenner M.K., Bollard C.M., Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013, 122:2965-2973.
39. Darcy P.K., John L.B., Neeson P., Henderson M.A., Kershaw M.H., Beavis P.A. Targeting tumor-induced immunosuppression leads to potent anti-tumor responses by CAR T cells 2014, Australasian Society for Immunology Annual Scientific Meeting 2014.
40. Davies D.M., Maher J. TSLPR: a new CAR in the showroom for B-ALL. Blood 2015, 126:567-569.
41. Davies D.M., Foster J., Van Der Stegen S.J., Parente-Pereira A.C., Chiapero-Stanke L., Delinassios G.J., Burbridge S.E., Kao V., Liu Z., Bosshard-Carter L., Van Schalkwyk M.C., Box C., Eccles S.A., Mather S.J., Wilkie S., Maher J. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 2012, 18:565-576.
42. Davila M.L., Riviere I., Wang X., Bartido S., Park J., Curran K., Chung S.S., Stefanski J., Borquez-Ojeda O., Olszewska M., Qu J., Wasielewska T., He Q., Fink M., Shinglot H., Youssif M., Satter M., Wang Y., Hosey J., Quintanilla H., Halton E., Bernal Y., Bouhassira D.C., Arcila M.E., Gonen M., Roboz G.J., Maslak P., Douer D., Frattini M.G., Giralt S., Sadelain M., Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6. 224ra225.
43. Di Stasi A., De Angelis B., Rooney C.M., Zhang L., Mahendravada A., Foster A.E., Heslop H.E., Brenner M.K., Dotti G., Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
44. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., Straathof K., Liu E., Durett A.G., Grilley B., Liu H., Cruz C.R., Savoldo B., Gee A.P., Schindler J., Krance R.A., Heslop H.E., Spencer D.M., Rooney C.M., Brenner M.K. Inducible apoptosis as a safety switch for adoptive cell therapy. New Engl. J. Med. 2011, 365:1673-1683.
45. Dohi O., Ohtani H., Hatori M., Sato E., Hosaka M., Nagura H., Itoi E., Kokubun S. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology 2009, 55:432-440.
46. Duong C.P., Westwood J.A., Yong C.S., Murphy A., Devaud C., John L.B., Darcy P.K., Kershaw M.H. Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLoS One 2013, 8:e63037.
47. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl. J. Med. 1986, 315:1650-1659.
48. Ene-Obong A., Clear A.J., Watt J., Wang J., Fatah R., Riches J.C., Marshall J.F., Chin-Aleong J., Chelala C., Gribben J.G., Ramsay A.G., Kocher H.M. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 2013, 145:1121-1132.
49. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:720-724.
50. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P., Gimotty P.A., Gilks C.B., Lal P., Zhang L., Coukos G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475:226-230.
51. Fedorov V.D., Themeli M., Sadelain M. PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 2013, 5. 215ra172.
52. Feig C., Jones J.O., Kraman M., Wells R.J., Deonarine A., Chan D.S., Connell C.M., Roberts E.W., Zhao Q., Caballero O.L., Teichmann S.A., Janowitz T., Jodrell D.I., Tuveson D.A., Fearon D.T. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20212-20217.
53. Finney H.M., Akbar A.N., Lawson A.D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 2004, 172:104-113.
54. Finney H.M., Lawson A.D., Bebbington C.R., Weir A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 1998, 161:2791-2797.
55. Fischer K., Hoffmann P., Voelkl S., Meidenbauer N., Ammer J., Edinger M., Gottfried E., Schwarz S., Rothe G., Hoves S., Renner K., Timischl B., Mackensen A., Kunz-Schughart L., Andreesen R., Krause S.W., Kreutz M. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109:3812-3819.
56. G.B B., O'Hara M.H., Nelson A.M., McGarvey M., Torigian D.A., Lacey S.F., Melenhorst J.J., Levine B., Plesa G., June C.H. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. J. Clin. Oncol. 2015, 2015 ASCO Annual Meeting, Chicago, Illinois, p. suppl; abstr 3007.
57. Galluzzi L., Senovilla L., Zitvogel L., Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 2012, 11:215-233.
58. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7235-7239.
59. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
60. Gattinoni L., Restifo N.P. Moving T memory stem cells to the clinic. Blood 2013, 121:567-568.
61. Geiger T.L., Nguyen P., Leitenberg D., Flavell R.A. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001, 98:2364-2371.
62. Gerweck L.E., Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 1996, 56:1194-1198.
63. Gil M., Komorowski M.P., Seshadri M., Rokita H., McGray A.J., Opyrchal M., Odunsi K.O., Kozbor D. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J. Immunol. 2014, 193:5327-5337.
64. Gill S., Tasian S.K., Ruella M., Shestova O., Li Y., Porter D.L., Carroll M., Danet-Desnoyers G., Scholler J., Grupp S.A., June C.H., Kalos M. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014, 123:2343-2354.
65. Giordano Attianese G.M., Marin V., Hoyos V., Savoldo B., Pizzitola I., Tettamanti S., Agostoni V., Parma M., Ponzoni M., Bertilaccio M.T., Ghia P., Biondi A., Dotti G., Biagi E. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood 2011, 117:4736-4745.
66. Gong M.C., Latouche J.B., Krause A., Heston W.D., Bander N.H., Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999, 1:123-127.
67. Grada Z., Hegde M., Byrd T., Shaffer D.R., Ghazi A., Brawley V.S., Corder A., Schonfeld K., Koch J., Dotti G., Heslop H.E., Gottschalk S., Wels W.S., Baker M.L., Ahmed N. TanCAR: a novel bispecific chimeric antigen receptor for Cancer immunotherapy. Mol. Ther. Nucleic Acids 2013, 2:e105.
68. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:10024-10028.
69. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., Milone M.C., Levine B.L., June C.H. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509-1518.
70. Guedan S., Carpenito C., McGettigan S.E., Frigault M.J., Scholler J., Zhao Y., June C.H. Redirection of TH17 cells with a car containing the ICOS costimulatory domain enhances function, antitumor activity and persistence of TH17 cells. Mol. Ther. 2012, 20:S130. Abstract 329.
71. Guest R.D., Hawkins R.E., Kirillova N., Cheadle E.J., Arnold J., O'Neill A., Irlam J., Chester K.A., Kemshead J.T., Shaw D.M., Embleton M.J., Stern P.L., Gilham D.E. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 2005, 28:203-211.
72. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T., Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3360-3365.
73. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
74. Hasmim M., Noman M.Z., Messai Y., Bordereaux D., Gros G., Baud V., Chouaib S. Cutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-beta1. J. Immunol. 2013, 191:5802-5806.
75. Hatfield S.M., Kjaergaard J., Lukashev D., Schreiber T.H., BelikoffB., Abbott R., Sethumadhavan S., Philbrook P., Ko K., Cannici R., Thayer M., Rodig S., Kutok J.L., Jackson E.K., Karger B., Podack E.R., Ohta A., Sitkovsky M.V. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med. 2015, 7. 277ra230.
76. Haynes N.M., Snook M.B., Trapani J.A., Cerruti L., Jane S.M., Smyth M.J., Darcy P.K. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J. Immunol. 2001, 166:182-187.
77. Hegde M., Corder A., Chow K.K., Mukherjee M., Ashoori A., Kew Y., Zhang Y.J., Baskin D.S., Merchant F.A., Brawley V.S., Byrd T.T., Krebs S., Wu M.F., Liu H., Heslop H.E., Gottschalk S., Yvon E., Ahmed N. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther.: J. Am. Soc. Gene Ther. 2013, 21:2087-2101.
78. Heimberger A.B., Hlatky R., Suki D., Yang D., Weinberg J., Gilbert M., Sawaya R., Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11:1462-1466.
79. Heslop H.E. Safer CARS. Mol. Ther.: J. Am. Soc. Gene Ther. 2010, 18:661-662.
80. Hodge J.W., Garnett C.T., Farsaci B., Palena C., Tsang K.Y., Ferrone S., Gameiro S.R. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer 2013, 133:624-636.
81. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 2010, 363:711-723.
82. Hombach A., Heuser C., Sircar R., Tillmann T., Diehl V., Kruis W., Pohl C., Abken H. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997, 113:1163-1170.
83. Hombach A., Koch D., Sircar R., Heuser C., Diehl V., Kruis W., Pohl C., Abken H. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 1999, 6:300-304.
84. Hudecek M., Sommermeyer D., Kosasih P.L., Silva-Benedict A., Liu L., Rader C., Jensen M.C., Riddell S.R. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 2015, 3:125-135.
85. Imai C., Mihara K., Andreansky M., Nicholson I.C., Pui C.H., Geiger T.L., Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
86. Irving B.A., Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991, 64:891-901.
87. John L.B., Devaud C., Duong C.P., Yong C.S., Beavis P.A., Haynes N.M., Chow M.T., Smyth M.J., Kershaw M.H., Darcy P.K. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:5636-5646.
88. Johnson L.A., Scholler J., Ohkuri T., Kosaka A., Patel P.R., McGettigan S.E., Nace A.K., Dentchev T., Thekkat P., Loew A., Boesteanu A.C., Cogdill A.P., Chen T., Fraietta J.A., Kloss C.C., Posey A.D., Engels B., Singh R., Ezell T., Idamakanti N., Ramones M.H., Li N., Zhou L., Plesa G., Seykora J.T., Okada H., June C.H., Brogdon J.L., Maus M.V. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 2015, 7. 275ra222.
89. Jonnalagadda M., Mardiros A., Urak R., Wang X., Hoffman L.J., Bernanke A., Chang W.C., BretzlaffW., Starr R., Priceman S., Ostberg J.R., Forman S.J., Brown C.E. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol. Ther.: J. Am. Soc. Gene Ther. 2015, 23:757-768.
90. Kahlon K.S., Brown C., Cooper L.J., Raubitschek A., Forman S.J., Jensen M.C. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004, 64:9160-9166.
91. Kakarla S., Chow K.K., Mata M., Shaffer D.R., Song X.T., Wu M.F., Liu H., Wang L.L., Rowley D.R., Pfizenmaier K., Gottschalk S. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol. Ther.: J. Am. Soc. Gene Ther. 2013, 21:1611-1620.
92. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., June C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3. 95ra73.
93. Kandalaft L.E., Powell D.J., Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J. Transl. Med. 2012, 10:157.
94. Katari U.L., Keirnan J.M., Worth A.C., Hodges S.E., Leen A.M., Fisher W.E., Vera J.F. Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 2011, 13:643-650.
95. Katz S.C., Burga R.A., McCormack E., Wang L.J., Mooring W., Point G.R., Khare P.D., Thorn M., Ma Q., Stainken B.F., Assanah E.O., Davies R., Espat N.J., Junghans R.P. Phase I hepatic immunotherapy for metastases study of intra-Arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2015, 21:3149-3159.
96. Kenderian S.S., Ruella M., Shestova O., Klichinsky M., Aikawa V., Morrissette J.J., Scholler J., Song D., Porter D.L., Carroll M., June C.H., Gill S. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 2015, 29:1637-1647.
97. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Canevari S., Rogers-Freezer L., Chen C.C., Yang J.C., Rosenberg S.A., Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
98. Kim H., Peng G., Hicks J.M., Weiss H.L., Van Meir E.G., Brenner M.K., Yotnda P. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol. Ther.: J. Am. Soc. Gene Ther. 2008, 16:599-606.
99. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 2013, 31:71-75.
100. Kochenderfer J.N., Dudley M.E., Carpenter R.O., Kassim S.H., Rose J.J., Telford W.G., Hakim F.T., Halverson D.C., Fowler D.H., Hardy N.M., Mato A.R., Hickstein D.D., Gea-Banacloche J.C., Pavletic S.Z., Sportes C., Maric I., Feldman S.A., Hansen B.G., Wilder J.S., Blacklock-Schuver B., Jena B., Bishop M.R., Gress R.E., Rosenberg S.A. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013, 122:4129-4139.
101. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., Yang J.C., Kammula U.S., Devillier L., Carpenter R., Nathan D.A., Morgan R.A., Laurencot C., Rosenberg S.A. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
102. Kochenderfer J.N., Dudley M.E., Kassim S.H., Somerville R.P., Carpenter R.O., Stetler-Stevenson M., Yang J.C., Phan G.Q., Hughes M.S., Sherry R.M., Raffeld M., Feldman S., Lu L., Li Y.F., Ngo L.T., Goy A., Feldman T., Spaner D.E., Wang M.L., Chen C.C., Kranick S.M., Nath A., Nathan D.A., Morton K.E., Toomey M.A., Rosenberg S.A. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2015, 33:540-549.
103. Kofler D., Chmielewski M., Rappl G., Hombach A., Riet T., Schmidt A., Hombach A., Wendtner C., Abken H. CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol. Ther.: J. Am. Soc. Gene Ther. 2011, 19:760-767.
104. Kong S., Sengupta S., Tyler B., Bais A.J., Ma Q., Doucette S., Zhou J., Sahin A., Carter B.S., Brem H., Junghans R.P., Sampath P. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2012, 18:5949-5960.
105. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., Gopinathan A., Tuveson D.A., Fearon D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
106. Krause A., Guo H.F., Latouche J.B., Tan C., Cheung N.K., Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 1998, 188:619-626.
107. Kudo K., Imai C., Lorenzini P., Kamiya T., Kono K., DavidoffA.M., Chng W.J., Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014, 74:93-103.
108. Kujawski M., Zhang C., Herrmann A., Reckamp K., Scuto A., Jensen M., Deng J., Forman S., Figlin R., Yu H. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 2010, 70:9599-9610.
109. Kuwana Y., Asakura Y., Utsunomiya N., Nakanishi M., Arata Y., Itoh S., Nagase F., Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 1987, 149:960-968.
110. Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther.: J. Am. Soc. Gene Ther. 2013, 21:904-912.
111. Lamers C.H., Sleijfer S., Vulto A.G., Kruit W.H., Kliffen M., Debets R., Gratama J.W., Stoter G., Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2006, 24:e20-22.
112. Lamers C.H., Willemsen R., van Elzakker P., van Steenbergen-Langeveld S., Broertjes M., Oosterwijk-Wakka J., Oosterwijk E., Sleijfer S., Debets R., Gratama J.W. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117:72-82.
113. Lanitis E., Poussin M., Hagemann I.S., Coukos G., Sandaltzopoulos R., Scholler N., Powell D.J. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol. Ther.: J. Am. Soc. Gene Ther. 2012, 20:633-643.
114. Lanitis E., Poussin M., KlattenhoffA.W., Song D., Sandaltzopoulos R., June C.H., Powell D.J. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 2013, 1:43-53.
115. Lee D.W., Gardner R., Porter D.L., Louis C.U., Ahmed N., Jensen M., Grupp S.A., Mackall C.L. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014, 124:188-195.
116. Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., Cui Y.K., Delbrook C., Feldman S.A., Fry T.J., Orentas R., Sabatino M., Shah N.N., Steinberg S.M., Stroncek D., Tschernia N., Yuan C., Zhang H., Zhang L., Rosenberg S.A., Wayne A.S., Mackall C.L. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015, 385:517-528.
117. Lesterhuis W.J., Punt C.J., Hato S.V., Eleveld-Trancikova D., Jansen B.J., Nierkens S., Schreibelt G., de Boer A., Van Herpen C.M., Kaanders J.H., van Krieken J.H., Adema G.J., Figdor C.G., de Vries I.J. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J. Clin. Invest. 2011, 121:3100-3108.
118. Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A., Chen J.Q., Li H.S., Watowich S.S., Yang Y., Tompers Frederick D., Cooper Z.A., Mbofung R.M., Whittington M., Flaherty K.T., Woodman S.E., Davies M.A., Radvanyi L.G., Overwijk W.W., Lizee G., Hwu P. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:393-403.
119. Lo A.S., Taylor J.R., Farzaneh F., Kemeny D.M., Dibb N.J., Maher J. Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Mol. Immunol. 2008, 45:1276-1287.
120. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., Rossig C., Russell H.V., Diouf O., Liu E., Liu H., Wu M.F., Gee A.P., Mei Z., Rooney C.M., Heslop H.E., Brenner M.K. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
121. Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol. 2012, 2012:278093.
122. Maher J. Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Curr. Gene Ther. 2014, 14:35-43.
123. Maher J., Brentjens R.J., Gunset G., Riviere I., Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 2002, 20:70-75.
124. Maine C.J., Aziz N.H., Chatterjee J., Hayford C., Brewig N., Whilding L., George A.J., Ghaem-Maghami S. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol. Immunother. 2014, 63:215-224.
125. Markley J.C., Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010, 115:3508-3519.
126. Maude S.L., Barrett D., Teachey D.T., Grupp S.A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014, 20:119-122.
127. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., Mahnke Y.D., Melenhorst J.J., Rheingold S.R., Shen A., Teachey D.T., Levine B.L., June C.H., Porter D.L., Grupp S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl. J. Med. 2014, 371:1507-1517.
128. Maude S.L., Teachey D.T., Porter D.L., Grupp S.A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015, 125:4017-4023.
129. Maus M.V., Haas A.R., Beatty G.L., Albelda S.M., Levine B.L., Liu X., Zhao Y., Kalos M., June C.H. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 2013, 1:26-31.
130. Melero I., Berman D.M., Aznar M.A., Korman A.J., Gracia J.L., Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 2015, 15:457-472.
131. Miao H., Choi B.D., Suryadevara C.M., Sanchez-Perez L., Yang S., De Leon G., Sayour E.J., McLendon R., Herndon J.E., Healy P., Archer G.E., Bigner D.D., Johnson L.A., Sampson J.H. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 2014, 9:e94281.
132. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., Samanta M., Lakhal M., Gloss B., Danet-Desnoyers G., Campana D., Riley J.L., Grupp S.A., June C.H. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther.: J. Am. Soc. Gene Ther. 2009, 17:1453-1464.
133. Molon B., Ugel S., Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., Savino B., Colombo P., Jonjic N., Pecanic S., Lazzarato L., Fruttero R., Gasco A., Bronte V., Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 2011, 208:1949-1962.
134. Moon E.K., Carpenito C., Sun J., Wang L.C., Kapoor V., Predina J., Powell D.J., Riley J.L., June C.H., Albelda S.M. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2011, 17:4719-4730.
135. Morgan R.A., Johnson L.A., Davis J.L., Zheng Z., Woolard K.D., Reap E.A., Feldman S.A., Chinnasamy N., Kuan C.T., Song H., Zhang W., Fine H.A., Rosenberg S.A. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 2012, 23:1043-1053.
136. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther.: J. Am. Soc. Gene Ther. 2010, 18:843-851.
137. Morgenroth A., Cartellieri M., Schmitz M., Gunes S., Weigle B., Bachmann M., Abken H., Rieber E.P., Temme A. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007, 67:1121-1131.
138. Mulligan J.K., Day T.A., Gillespie M.B., Rosenzweig S.A., Young M.R. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum. Immunol. 2009, 70:375-382.
139. Muniappan A., Banapour B., Lebkowski J., Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther. 2000, 7:128-134.
140. Nakagawa Y., Negishi Y., Shimizu M., Takahashi M., Ichikawa M., Takahashi H. Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes. Immunol. Lett. 2015, 167(2):72-86.
141. Nishio N., Diaconu I., Liu H., Cerullo V., Caruana I., Hoyos V., Bouchier-Hayes L., Savoldo B., Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014, 74:5195-5205.
142. Noman M.Z., Buart S., Romero P., Ketari S., Janji B., Mari B., Mami-Chouaib F., Chouaib S. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012, 72:4629-4641.
143. Ohta A., Gorelik E., Prasad S.J., Ronchese F., Lukashev D., Wong M.K., Huang X., Caldwell S., Liu K., Smith P., Chen J.F., Jackson E.K., Apasov S., Abrams S., Sitkovsky M. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13132-13137.
144. Ohta A., Kjaergaard J., Sharma S., Mohsin M., Goel N., Madasu M., Fradkov E., Ohta A., Sitkovsky M. In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br. J. Pharmacol. 2009, 156:297-306.
145. Ozao-Choy J., Ma G., Kao J., Wang G.X., Meseck M., Sung M., Schwartz M., Divino C.M., Pan P.Y., Chen S.H. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009, 69:2514-2522.
146. Pameijer C.R., Navanjo A., Meechoovet B., Wagner J.R., Aguilar B., Wright C.L., Chang W.C., Brown C.E., Jensen M.C. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 2007, 14:91-97.
147. Papa S., van Schalkwyk M., Maher J. Clinical evaluation of ErbB-targeted CAR T-cells, following intracavity delivery in patients with ErbB-expressing solid tumors. Methods Mol. Biol. 2015, 1317:365-382.
148. Parente-Pereira A.C., Burnet J., Ellison D., Foster J., Davies D.M., van der Stegen S., Burbridge S., Chiapero-Stanke L., Wilkie S., Mather S., Maher J. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 2011, 31:710-718.
149. Parente-Pereira A.C., Whilding L.M., Brewig N., van der Stegen S.J., Davies D.M., Wilkie S., van Schalkwyk M.C., Ghaem-Maghami S., Maher J. Synergistic chemoimmunotherapy of epithelial ovarian Cancer using ErbB-retargeted T cells combined with carboplatin. J. Immunol. 2013, 191:2437-2445.
150. Park J.H., Riviere I., Wang X., Bernal Y., Purdon T., Halton E., Curran K.J., Sauter C.S., Sadelain M., Brentjens R.J. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. J. Clin. Oncol. 2015, 2015 ASCO Annual Meeting, Chicago, Illinois, p. suppl; abstr 7010.
151. Park J.R., Digiusto D.L., Slovak M., Wright C., Naranjo A., Wagner J., Meechoovet H.B., Bautista C., Chang W.C., Ostberg J.R., Jensen M.C. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther.: J. Am. Soc. Gene Ther. 2007, 15:825-833.
152. Pearce E.L., Walsh M.C., Cejas P.J., Harms G.M., Shen H., Wang L.S., Jones R.G., Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.
153. Pegram H.J., Lee J.C., Hayman E.G., Imperato G.H., Tedder T.F., Sadelain M., Brentjens R.J. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012, 119:4133-4141.
154. Peng W., Liu C., Xu C., Lou Y., Chen J., Yang Y., Yagita H., Overwijk W.W., Lizee G., Radvanyi L., Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012, 72:5209-5218.
155. Peng W., Ye Y., Rabinovich B.A., Liu C., Lou Y., Zhang M., Whittington M., Yang Y., Overwijk W.W., Lizee G., Hwu P. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:5458-5468.
156. Petrausch U., Schuberth P.C., Hagedorn C., Soltermann A., Tomaszek S., Stahel R., Weder W., Renner C. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer 2012, 12:615.
157. Philip B., Kokalaki E., Mekkaoui L., Thomas S., Straathof K., Flutter B., Marin V., Marafioti T., Chakraverty R., Linch D., Quezada S.A., Peggs K.S., Pule M. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 2014, 124:1277-1287.
158. Pinthus J.H., Waks T., Malina V., Kaufman-Francis K., Harmelin A., Aizenberg I., Kanety H., Ramon J., Eshhar Z. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. 2004, 114:1774-1781.
159. Pizzitola I., Anjos-Afonso F., Rouault-Pierre K., Lassailly F., Tettamanti S., Spinelli O., Biondi A., Biagi E., Bonnet D. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014, 28:1596-1605.
160. Poirot L., Philip B., Schiffer-Mannioui C., Le Clerre D., Chion-Sotinel I., Derniame S., Bas C., Potrel P., Lemaire L., Duclert A., Galetto R., Lebuhotel C., Eyquem J., Cheung G.W., Gouble A., Arnould S., Peggs K.S., Pule M., Scharenberg A., Smith J. Multiplex genome edited T-cell manufacturing platform for "off-the-shelf" adoptive T-cell immunotherapies. Cancer Res. 2015, 75(18):3853-3864.
161. Pol J., Vacchelli E., Aranda F., Castoldi F., Eggermont A., Cremer I., Sautes-Fridman C., Fucikova J., Galon J., Spisek R., Tartour E., Zitvogel L., Kroemer G., Galluzzi L. Trial Watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 2015, 4:e1008866.
162. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
163. Proietti E., Moschella F., Capone I., Belardelli F. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol. Oncol. 2012, 6:1-14.
164. Provasi E., Genovese P., Lombardo A., Magnani Z., Liu P.Q., Reik A., Chu V., Paschon D.E., Zhang L., Kuball J., Camisa B., Bondanza A., Casorati G., Ponzoni M., Ciceri F., Bordignon C., Greenberg P.D., Holmes M.C., Gregory P.D., Naldini L., Bonini C. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 2012, 18:807-815.
165. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., Huls M.H., Liu E., Gee A.P., Mei Z., Yvon E., Weiss H.L., Liu H., Rooney C.M., Heslop H.E., Brenner M.K. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008, 14:1264-1270.
166. Pule M.A., Straathof K.C., Dotti G., Heslop H.E., Rooney C.M., Brenner M.K. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 2005, 12:933-941.
167. Qin H., Cho M., Haso W., Zhang L., Tasian S.K., Oo H.Z., Negri G.L., Lin Y., Zou J., Mallon B.S., Maude S., Teachey D.T., Barrett D.M., Orentas R.J., Daugaard M., Sorensen P.H., Grupp S.A., Fry T.J. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 2015, 126:629-639.
168. Quintarelli C., Vera J.F., Savoldo B., Giordano Attianese G.M., Pule M., Foster A.E., Heslop H.E., Rooney C.M., Brenner M.K., Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007, 110:2793-2802.
169. Rainusso N., Brawley V.S., Ghazi A., Hicks M.J., Gottschalk S., Rosen J.M., Ahmed N. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 2012, 19:212-217.
170. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.I., Antonia S., Altiok S., Celis E., Gabrilovich D.I. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010, 120:1111-1124.
171. Riddell S.R., Sommermeyer D., Berger C., Liu L.S., Balakrishnan A., Salter A., Hudecek M., Maloney D.G., Turtle C.J. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J. 2014, 20:141-144.
172. Righi E., Kashiwagi S., Yuan J., Santosuosso M., Leblanc P., Ingraham R., Forbes B., Edelblute B., Collette B., Xing D., Kowalski M., Mingari M.C., Vianello F., Birrer M., Orsulic S., DranoffG., Poznansky M.C. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011, 71:5522-5534.
173. Ritchie D.S., Neeson P.J., Khot A., Peinert S., Tai T., Tainton K., Chen K., Shin M., Wall D.M., Honemann D., Gambell P., Westerman D.A., Haurat J., Westwood J.A., Scott A.M., Kravets L., Dickinson M., Trapani J.A., Smyth M.J., Darcy P.K., Kershaw M.H., Prince H.M. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther.: J. Am. Soc. Gene Ther. 2013, 21:2122-2129.
174. Saied A., Licata L., Burga R.A., Thorn M., McCormack E., Stainken B.F., Assanah E.O., Khare P.D., Davies R., Espat N.J., Junghans R.P., Katz S.C. Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Ther. 2014, 21:457-462.
175. Salmon H., Franciszkiewicz K., Damotte D., Dieu-Nosjean M.C., Validire P., Trautmann A., Mami-Chouaib F., Donnadieu E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 2012, 122:899-910.
176. Sampson J.H., Choi B.D., Sanchez-Perez L., Suryadevara C.M., Snyder D.J., Flores C.T., Schmittling R.J., Nair S.K., Reap E.A., Norberg P.K., Herndon J.E., Kuan C.T., Morgan R.A., Rosenberg S.A., Johnson L.A. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2014, 20:972-984.
177. Savoldo B., Ramos C.A., Liu E., Mims M.P., Keating M.J., Carrum G., Kamble R.T., Bollard C.M., Gee A.P., Mei Z., Liu H., Grilley B., Rooney C.M., Heslop H.E., Brenner M.K., Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 2011, 121:1822-1826.
178. Schlie K., Spowart J.E., Hughson L.R., Townsend K.N., Lum J.J. When cells suffocate: autophagy in cancer and immune cells under low oxygen. Int. J. Cel. Biol. 2011, 2011:470597.
179. Schuberth P.C., Hagedorn C., Jensen S.M., Gulati P., van den Broek M., Mischo A., Soltermann A., Jungel A., Marroquin Belaunzaran O., Stahel R., Renner C., Petrausch U. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 2013, 11:187.
180. Schuster S.J., Svoboda J., Nasta S., Porter D.L., Mato A., Shah G.D., Landsburg D.J., Chong E.A., Lacey S.F., Melenhorst J.J., Chew A., Hasskarl J., Shah N.N., Wasik M.A., Marcucci K., Zheng Z., Levine B., June C.H. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. J. Clin. Oncol. 2015, 2015 ASCO Annual Meeting, Chicag, Illinois, p. suppl; abstr 8516.
181. Scotton C.J., Wilson J.L., Scott K., Stamp G., Wilbanks G.D., Fricker S., Bridger G., Balkwill F.R. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002, 62:5930-5938.
182. Sharifzadeh Z., Rahbarizadeh F., Shokrgozar M.A., Ahmadvand D., Mahboudi F., Jamnani F.R., Moghimi S.M. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett. 2013, 334:237-244.
183. Sheen A.J., Sherlock D.J., Irlam J., Hawkins R.E., Gilham D.E. T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br. J. Cancer 2003, 88:1119-1127.
184. Shrimali R.K., Yu Z., Theoret M.R., Chinnasamy D., Restifo N.P., Rosenberg S.A. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010, 70:6171-6180.
185. Sitkovsky M.V., Hatfield S., Abbott R., BelikoffB., Lukashev D., Ohta A. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol. Res. 2014, 2:598-605.
186. Smith J., Poirot L., Philip B., Schiffer-Mannoui C., Derniame S., Zhan H., Stafford S., Reynier S., Arnould S., Gouble A., Qasim W., Peggs K., Pule M., Sourdive D. UCART19, an allogeneic "off-the-shelf" adoptive T-cell immunotherapy against CD19+ B-cell leukemias. J. Clin. Oncol. 2015, ASCO Annual Meeting, p. (suppl; abstr 3069).
187. Song D.G., Ye Q., Carpenito C., Poussin M., Wang L.P., Ji C., Figini M., June C.H., Coukos G., Powell D.J. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71:4617-4627.
188. Song D.G., Ye Q., Poussin M., Harms G.M., Figini M., Powell D.J. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012, 119:696-706.
189. Stephan M.T., Ponomarev V., Brentjens R.J., Chang A.H., Dobrenkov K.V., Heller G., Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 2007, 13:1440-1449.
190. Straathof K.C., Pule M.A., Yotnda P., Dotti G., Vanin E.F., Brenner M.K., Heslop H.E., Spencer D.M., Rooney C.M. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105:4247-4254.
191. Sukumar M., Liu J., Ji Y., Subramanian M., Crompton J.G., Yu Z., Roychoudhuri R., Palmer D.C., Muranski P., Karoly E.D., Mohney R.P., KlebanoffC.A., Lal A., Finkel T., Restifo N.P., Gattinoni L. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest. 2013, 123:4479-4488.
192. Sun M., Shi H., Liu C., Liu J., Liu X., Sun Y. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res. 2014, 16:R61.
193. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117:1137-1146.
194. Tamada K., Geng D., Sakoda Y., Bansal N., Srivastava R., Li Z., Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2012, 18:6436-6445.
195. Tammana S., Huang X., Wong M., Milone M.C., Ma L., Levine B.L., June C.H., Wagner J.E., Blazar B.R., Zhou X. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 2010, 21:75-86.
196. Tanyi J.L., Haas A.R., Beatty G.R., Morgan M.A., Stashwick C.J., O'Hara M.H., Porter D.L., Maus M.V., Levine B.L., Lacey S.F., Nelson A.M., McGarvey M., Kerr N.D.S., Plesa G., June C.H. Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers 2015, Proceedings of the American Association for Cancer Research Meeting, Philadelphia, Pennsylvania, Abstract number CT105.
197. Teo P.Y., Yang C., Whilding L.M., Parente-Pereira A.C., Maher J., George A.J., Hedrick J.L., Yang Y.Y., Ghaem-Maghami S. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing. Adv. Healthc. Mater. 2015, 4:1180-1189.
198. Themeli M., Kloss C.C., Ciriello G., Fedorov V.D., Perna F., Gonen M., Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 2013, 31:928-933.
199. Themeli M., Riviere I., Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 2015, 16:357-366.
200. Thompson R.H., Kuntz S.M., Leibovich B.C., Dong H., Lohse C.M., Webster W.S., Sengupta S., Frank I., Parker A.S., Zincke H., Blute M.L., Sebo T.J., Cheville J.C., Kwon E.D. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006, 66:3381-3385.
201. Till B.G., Jensen M.C., Wang J., Chen E.Y., Wood B.L., Greisman H.A., Qian X., James S.E., Raubitschek A., Forman S.J., Gopal A.K., Pagel J.M., Lindgren C.G., Greenberg P.D., Riddell S.R., Press O.W. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
202. Till B.G., Jensen M.C., Wang J., Qian X., Gopal A.K., Maloney D.G., Lindgren C.G., Lin Y., Pagel J.M., Budde L.E., Raubitschek A., Forman S.J., Greenberg P.D., Riddell S.R., Press O.W. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940-3950.
203. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl. J. Med. 2012, 366:2443-2454.
204. Topp M.S., Gokbuget N., Zugmaier G., Klappers P., Stelljes M., Neumann S., Viardot A., Marks R., Diedrich H., Faul C., Reichle A., Horst H.A., Bruggemann M., Wessiepe D., Holland C., Alekar S., Mergen N., Einsele H., Hoelzer D., Bargou R.C. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2014, 32:4134-4140.
205. Torikai H., Reik A., Liu P.Q., Zhou Y., Zhang L., Maiti S., Huls H., Miller J.C., Kebriaei P., Rabinovitch B., Lee D.A., Champlin R.E., Bonini C., Naldini L., Rebar E.J., Gregory P.D., Holmes M.C., Cooper L.J. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012, 119:5697-5705.
206. Tran E., Chinnasamy D., Yu Z., Morgan R.A., Lee C.C., Restifo N.P., Rosenberg S.A. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 2013, 210:1125-1135.
207. Traversari C., Marktel S., Magnani Z., Mangia P., Russo V., Ciceri F., Bonini C., Bordignon C. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007, 109:4708-4715.
208. Urbanska K., Lanitis E., Poussin M., Lynn R.C., Gavin B.P., Kelderman S., Yu J., Scholler N., Powell D.J. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012, 72:1844-1852.
209. Valton J., Guyot V., Marechal A., Filhol J.M., Juillerat A., Duclert A., Duchateau P., Poirot L. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol. Ther.: J. Am. Soc. Gene Ther. 2015, 23(9):1507-1518.
210. van der Stegen S.J., Davies D.M., Wilkie S., Foster J., Sosabowski J.K., Burnet J., Whilding L.M., Petrovic R.M., Ghaem-Maghami S., Mather S., Jeannon J.P., Parente-Pereira A.C., Maher J. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?. J. Immunol. 2013, 191:4589-4598.
211. van der Stegen S.J., Hamieh M., Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nature reviews. Drug Discov. 2015, 14:499-509.
212. van Schalkwyk M.C., Papa S.E., Jeannon J.P., Guerrero Urbano T., Spicer J.F., Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 2013, 24:134-142.
213. Vanneman M., DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12:237-251.
214. Vinay D.S., Ryan E.P., Pawelec G., Talib W.H., Stagg J., Elkord E., Lichtor T., Decker W.K., Whelan R.L., Kumara H.M., Signori E., Honoki K., Georgakilas A.G., Amin A., Helferich W.G., Boosani C.S., Guha G., Ciriolo M.R., Chen S., Mohammed S.I., Azmi A.S., Keith W.N., Bilsland A., Bhakta D., Halicka D., Fujii H., Aquilano K., Ashraf S.S., Nowsheen S., Yang X., Choi B.K., Kwon B.S. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 2015, (in press). http://dx.doi.org/10.1016/j.semcancer.2015.03.004.
215. Wang E., Wang L.C., Tsai C.Y., Bhoj V., Gershenson Z., Moon E., Newick K., Sun J., Lo A., Baradet T., Feldman M.D., Barrett D., Pure E., Albelda S., Milone M.C. Generation of potent T-cell immunotherapy for Cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol. Res. 2015, 3:815-826.
216. Wang L.C., Lo A., Scholler J., Sun J., Majumdar R.S., Kapoor V., Antzis M., Cotner C.E., Johnson L.A., Durham A.C., Solomides C.C., June C.H., Pure E., Albelda S.M. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2014, 2:154-166.
217. Wang X., Chang W.C., Wong C.W., Colcher D., Sherman M., Ostberg J.R., Forman S.J., Riddell S.R., Jensen M.C. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011, 118:1255-1263.
218. Wang Y., Zhang W.Y., Han Q.W., Liu Y., Dai H.R., Guo Y.L., Bo J., Fan H., Zhang Y., Zhang Y.J., Chen M.X., Feng K.C., Wang Q.S., Fu X.B., Han W.D. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin. Immunol. 2014, 155:160-175.
219. Warburg O., Wind F., Negelein E. The metabolism of tumors in the Body. J. Gen. Physiol. 1927, 8:519-530.
220. Watanabe K., Terakura S., Martens A.C., van Meerten T., Uchiyama S., Imai M., Sakemura R., Goto T., Hanajiri R., Imahashi N., Shimada K., Tomita A., Kiyoi H., Nishida T., Naoe T., Murata M. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells. J. Immunol. 2015, 194:911-920.
221. Watt J., Kocher H.M. The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. Oncoimmunology 2013, 2:e26788.
222. Weishaupt C., Munoz K.N., Buzney E., Kupper T.S., Fuhlbrigge R.C. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2007, 13:2549-2556.
223. Wilkie S., Burbridge S.E., Chiapero-Stanke L., Pereira A.C., Cleary S., van der Stegen S.J., Spicer J.F., Davies D.M., Maher J. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 2010, 285:25538-25544.
224. Wilkie S., Picco G., Foster J., Davies D.M., Julien S., Cooper L., Arif S., Mather S.J., Taylor-Papadimitriou J., Burchell J.M., Maher J. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 2008, 180:4901-4909.
225. Wilkie S., van Schalkwyk M.C., Hobbs S., Davies D.M., van der Stegen S.J., Pereira A.C., Burbridge S.E., Box C., Eccles S.A., Maher J. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 2012, 32:1059-1070.
226. Wu A.A., Drake V., Huang H.S., Chiu S., Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015, 4:e1016700.
227. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl. J. Med. 2003, 348:203-213.
228. Zhang L., Kerkar S.P., Yu Z., Zheng Z., Yang S., Restifo N.P., Rosenberg S.A., Morgan R.A. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 2011, 19:751-759.
229. Zhao Y., Wang Q.J., Yang S., Kochenderfer J.N., Zheng Z., Zhong X., Sadelain M., Eshhar Z., Rosenberg S.A., Morgan R.A. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 2009, 183:5563-5574.
230. Zhong X.S., Matsushita M., Plotkin J., Riviere I., Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther.: J. Am. Soc. Gene Ther. 2010, 18:413-420.
231. Zhou X., Di Stasi A., Tey S.K., Krance R.A., Martinez C., Leung K.S., Durett A.G., Wu M.F., Liu H., Leen A.M., Savoldo B., Lin Y.F., Grilley B.J., Gee A.P., Spencer D.M., Rooney C.M., Heslop H.E., Brenner M.K., Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 2014, 123:3895-3905.
232. Zhou X., Dotti G., Krance R.A., Martinez C.A., Naik S., Kamble R.T., Durett A.G., Dakhova O., Savoldo B., Di Stasi A., Spencer D.M., Lin Y.F., Liu H., Grilley B.J., Gee A.P., Rooney C.M., Heslop H.E., Brenner M.K. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 2015, 125:4103-4113.
233. Zhou X., Li J., Wang Z., Chen Z., Qiu J., Zhang Y., Wang W., Ma Y., Huang N., Cui K., Li J., Wei Y.Q. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia 2013, 15:544-553.
234. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8:59-73.